Stoke Therapeutics (NASDAQ:STOK) Lowered to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of Stoke Therapeutics (NASDAQ:STOK – Get Rating) from a buy rating to a hold rating in a report published on Wednesday morning, Zacks.com reports. According to Zacks, “Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company’s product candidate consists of STK-001 […]

Related Keywords

California ,United States ,Bedford ,Massachusetts ,America ,Adrianr Krainer ,Huwm Nash ,Isabel Aznarez ,Securities Exchange Commission ,Goldman Sachs Group Inc ,Zacks Investment Research ,Nuveen Asset Management ,Stoke Therapeutics Inc ,Highvista Strategies ,Jpmorgan Chase Co ,Jefferies Financial Group ,Stoke Therapeutics ,Get Rating ,Exchange Commission ,Sachs Group ,Asset Management ,State Teachers Retirement System ,Vista Strategies ,State Street Corp ,Street Corp ,Nasdaq Stok ,Istok ,Medical ,Downgrade ,